LAVAL,
QC, June 23, 2022 /PRNewswire/ -- Bausch
Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the
"Company") today announced the results of its 2022 annual meeting
of shareholders and certain other updates with respect to the
Company's Board of Directors (the "Board").
Annual Meeting Results
The 12 directors nominated at the Company's 2022 annual meeting
of shareholders held on June 21, 2022
were elected by a vote of the shareholders. The detailed results of
the vote for the election of directors are set out below:
Name
|
For
|
Withheld
|
Broker
Non-Votes
|
Thomas J.
Appio
|
208,484,011
|
4,473,053
|
70,926,205
|
Richard U. De
Schutter
|
204,019,165
|
8,937,899
|
70,926,205
|
Brett Icahn
|
202,357,292
|
10,599,772
|
70,926,205
|
Dr. Argeris (Jerry) N.
Karabelas
|
201,356,586
|
11,600,478
|
70,926,205
|
Sarah B.
Kavanagh
|
204,141,525
|
8,815,539
|
70,926,205
|
Steven D.
Miller
|
203,021,418
|
9,935,646
|
70,926,205
|
Dr. Richard C.
Mulligan
|
195,477,842
|
17,479,222
|
70,926,205
|
Joseph C.
Papa
|
176,759,880
|
36,197,184
|
70,926,205
|
Robert N.
Power
|
153,014,215
|
59,942,849
|
70,926,205
|
Russel C.
Robertson
|
199,201,436
|
13,755,628
|
70,926,205
|
Thomas W. Ross,
Sr.
|
199,710,479
|
13,246,585
|
70,926,205
|
Amy B. Wechsler,
M.D.
|
204,605,343
|
8,351,721
|
70,926,205
|
At the annual meeting of shareholders, shareholders also
approved in a non-binding advisory vote the compensation of the
Company's named executive officers, approved amendments to the
Company's 2014 Omnibus Incentive Plan and appointed
PricewaterhouseCoopers LLP as the Company's independent registered
public accounting firm until the close of the Company's 2023 annual
meeting of shareholders.
The final vote tabulation on all matters voted on at the meeting
will be reported to the U.S. Securities and Exchange Commission on
a current report on Form 8-K, and such report will be made
available on the Company's SEDAR profile and on the Company's
website at www.bauschhealth.com.
Updates to Board of Directors
The Company also announced today that Joseph C. Papa resigned from the Board,
effective immediately. Mr. Papa's decision to resign from the Board
was not due to any dispute or disagreement with the Company, its
management or the Board on any matter relating to the Company's
operations, policies or practices.
The Board appointed John A.
Paulson to the Board to fill the resulting vacancy,
effective upon Mr. Papa's resignation. Mr. Paulson will also serve
as the Chairperson of the Board. The Board has not determined at
this time the committees, if any, to which Mr. Paulson will be
appointed. Pursuant to the Company's Corporate Governance
Guidelines, because Mr. Paulson is an independent director, the
Board will no longer have the position of Lead Independent
Director. The current Lead Independent Director, Mr. Ross, will
continue to serve on the Board.
Mr. Paulson currently serves as an independent director of
Bausch + Lomb Corporation. He also previously served on the board
of the Company from June 2017 to
May 2022. Mr. Paulson is the
President and Portfolio Manager of Paulson & Co. Inc., an
investment management company, which he founded in 1994. Mr.
Paulson has been a Chairman of the Board of BrightSphere Investment
Group Inc., a publicly traded asset management holding company,
since April 2020, and has been a
director since 2018. He also currently serves as a member of the
advisory board of Harvard Business
School. Mr. Paulson previously served as a director of
American International Group Inc., a multinational finance and
insurance corporation, from May 2016
to June 2017.
"The Company and the Board of Directors would like to thank Mr.
Papa for his leadership over the past six years. Joe oversaw
significant change in the business during his tenure and we
appreciate his role in Bausch Health's continued transformation,"
said CEO Thomas J. Appio.
"I am excited about the Company's future and its potential to
create shareholder value," added John
Paulson.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global diversified pharmaceutical company
whose mission is to improve people's lives with our health care
products. We develop, manufacture and market a range of products
primarily in gastroenterology, hepatology, neurology, dermatology,
international pharmaceuticals and eye health, through our
approximately 90% ownership of Bausch + Lomb Corporation. With our
leading durable brands, we are delivering on our commitments as we
build an innovative company dedicated to advancing global health.
For more information, visit www.bauschhealth.com and connect
with us on Twitter and LinkedIn.
Forward-looking Statements
This news release may
contain forward-looking statements about Bausch Health, which may
generally be identified by the use of the words "anticipates,"
"hopes," "expects," "intends," "plans," "should," "could," "would,"
"may," "believes," "subject to" and variations or similar
expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
In addition, actual results are subject to other risks and
uncertainties that relate more broadly to Bausch Health's overall
business, including those more fully described in Bausch Health's
filings with the U.S. Securities and Exchange Commission and the
Canadian Securities Administrators, which factors are incorporated
herein by reference. Readers are cautioned not to place undue
reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof. Bausch
Health undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this news release or to reflect actual outcomes, unless
required by law.
Investor
Contact:
|
Media
Contact:
|
Christina
Cheng
|
Lainie
Keller
|
christina.cheng@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bausch-health-announces-2022-annual-meeting-of-shareholder-results-updates-to-its-board-of-directors-301574477.html
SOURCE Bausch Health Companies Inc.